Last reviewed · How we verify
Oral chenodeoxycholic acid stimulation
Chenodeoxycholic acid is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling pathways to regulate bile acid metabolism and reduce cholestasis.
Chenodeoxycholic acid is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling pathways to regulate bile acid metabolism and reduce cholestasis. Used for Progressive familial intrahepatic cholestasis (PFIC), Bile acid synthesis disorders, Cholestatic liver disease.
At a glance
| Generic name | Oral chenodeoxycholic acid stimulation |
|---|---|
| Also known as | Chenodeoxycolic acid |
| Sponsor | Lars Kristian Munck |
| Drug class | Bile acid receptor agonist |
| Target | FXR (farnesoid X receptor), TGR5 |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Chenodeoxycholic acid (CDCA) is an endogenous secondary bile acid that acts as a ligand for nuclear farnesoid X receptor (FXR) and G-protein coupled receptor TGR5. Upon oral administration, it enhances bile acid-dependent signaling to suppress hepatic bile acid synthesis, increase bile acid excretion, and improve cholestatic liver disease. This mechanism reduces the accumulation of toxic bile acids in the liver and improves hepatic and intestinal function.
Approved indications
- Progressive familial intrahepatic cholestasis (PFIC)
- Bile acid synthesis disorders
- Cholestatic liver disease
Common side effects
- Pruritus
- Diarrhea
- Abdominal discomfort
- Steatorrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral chenodeoxycholic acid stimulation CI brief — competitive landscape report
- Oral chenodeoxycholic acid stimulation updates RSS · CI watch RSS
- Lars Kristian Munck portfolio CI